Peptide-displaying chimeric AAV vectors with increased skeletal muscle potency and liver detargeting for systemic gene therapy - Approches génétiques intégrées et nouvelles thérapies pour les maladies rares Access content directly
Conference Poster Year : 2022

Peptide-displaying chimeric AAV vectors with increased skeletal muscle potency and liver detargeting for systemic gene therapy

Jihad El Andari
  • Function : Author
Louise Mangin
  • Function : Author
Jonas Weinmann
  • Function : Author
Esther Attebi
  • Function : Author
Emanuele Bourges
  • Function : Author
Christian Leborgne
Nicolas Guerchet
  • Function : Author
Julia Fakhiri
  • Function : Author
Chiara Krämer
  • Function : Author
Ellen Wiedtke
  • Function : Author
Laurence Guianvarc’h
Magali Toueille
  • Function : Author
Giuseppe Ronzitti
Matthias Hebben
Federico Mingozzi
Dirk Grimm
  • Function : Author
Ana Buj-Bello

Abstract

Bioengineering of adeno-associated viral (AAV) vectors is a pivotal strategy for developing next-generation gene therapies for human disorders. In the present study, we assessed the efficacy of two novel AAV vectors, AAVMYO2 and AAVMYO3, which are composed of hybrid capsids and a small VP1 peptide insertion, in a mouse model of myotubular myopathy, a severe inherited disease affecting skeletal muscles that is caused by loss-of-function mutations in the MTM1 gene. Intravenous administration of either AAVMYO2- or AAVMYO3-MTM1 vectors at 2x1013 vg/kg in Mtm1-KO mice prolonged their lifespan, corrected the histopathological hallmarks of the disease and muscle strength for a period of at least 3 months, and resulted in liver transduction detargeting. Therefore, our findings indicate that these novel vectors are efficacious in rescuing the phenotype of myotubular myopathy in mice. In addition, we show efficient large-scale production and purification of AAVMYO2 and AAVMYO3, and data on their seroprevalence in a cohort of human sera. Altogether these results show that the novel AAVMYO2 and AAVMYO3 capsids enable potent muscle delivery of therapeutic genes.
Fichier principal
Vignette du fichier
Poster Myology2022ERG.pdf (1.2 Mo) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-04442190 , version 1 (06-02-2024)

Identifiers

  • HAL Id : hal-04442190 , version 1

Cite

Edith Renaud-Gabardos, Jihad El Andari, Louise Mangin, Jonas Weinmann, Esther Attebi, et al.. Peptide-displaying chimeric AAV vectors with increased skeletal muscle potency and liver detargeting for systemic gene therapy. Myology 2022, Sep 2022, Nice, France. ⟨hal-04442190⟩
12 View
3 Download

Share

Gmail Facebook X LinkedIn More